EUVIMEDEUVIMED entdecken
Crossref

Toxicities and outcome after CD19 ‐directed chimeric antigen receptor T‐cell therapy for secondary neurolymphomatosis

Leon D Kaulen iD, Philipp Karschnia, Sofia Doubrovinskaia, Jeremy S Abramson, Maria Martinez-Lage, Ganesh Shankar, Bryan D Choi, Jeffrey A Barnes, Areej El-Jawahri, Ephraim P Hochberg, P Connor Johnson, Jacob D Soumerai und 5 weitere

American Journal of Hematology · 2024

DOI: 10.1002/ajh.27505 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Leon D Kaulen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Antigens, CD19, Immunotherapy, Adoptive, Neurolymphomatosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, CD19Immunotherapy, AdoptiveNeurolymphomatosisHumansMaleMiddle AgedFemaleAgedRetrospective StudiesReceptors, Chimeric AntigenAdultCytokine Release SyndromeTreatment Outcome

Substanzen

Antigens, CD19Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Neurology, University Hospital Heidelberg, Heidelberg University, Heidelberg, Germany.
  • Clinical Cooperation Unit Neuro-Oncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.
  • Department of Neurosurgery, Ludwig Maximilians University (LMU), Munich, Germany.
  • Department of Neurosurgery, Friedrich-Alexander-University Erlangen/Nuernberg, Erlangen, Germany.
  • Department of Medicine, Hematology, and Oncology Division, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Leon D Kaulen

Zitieren

APA

Kaulen, L. D., Karschnia, P., Doubrovinskaia, S., Abramson, J. S., Martinez-Lage, M., Shankar, G., Choi, B. D., Barnes, J. A., El-Jawahri, A., Hochberg, E. P., Johnson, P. C., Soumerai, J. D., Wick, W., Maus, M. V., Chen, Y. B., Frigault, M. J., & Dietrich, J. (2024). Toxicities and outcome after CD19 ‐directed chimeric antigen receptor T‐cell therapy for secondary neurolymphomatosis. American Journal of Hematology. https://doi.org/10.1002/ajh.27505

Vancouver

Kaulen LD, Karschnia P, Doubrovinskaia S, Abramson JS, Martinez-Lage M, Shankar G, et al. Toxicities and outcome after CD19 ‐directed chimeric antigen receptor T‐cell therapy for secondary neurolymphomatosis. American Journal of Hematology. 2024. doi:10.1002/ajh.27505

BibTeX
@article{Kaulen2024,
  author = {Kaulen, Leon D and Karschnia, Philipp and Doubrovinskaia, Sofia and Abramson, Jeremy S and Martinez-Lage, Maria and Shankar, Ganesh and Choi, Bryan D and Barnes, Jeffrey A and El-Jawahri, Areej and Hochberg, Ephraim P and Johnson, P Connor and Soumerai, Jacob D and Wick, Wolfgang and Maus, Marcela V and Chen, Yi-Bin and Frigault, Matthew J and Dietrich, Jorg},
  title = {Toxicities and outcome after CD19 ‐directed chimeric antigen receptor T‐cell therapy for secondary neurolymphomatosis},
  journal = {American Journal of Hematology},
  year = {2024},
  doi = {10.1002/ajh.27505}
}
Kostenlos starten →